1318. Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment

BACKGROUND: Taniborbactam is a novel, non-ß-lactam, ß-lactamase inhibitor with activity against serine (Class A, C, D) and metallo (Class B) ß-lactamases including epidemiologically important carbapenemases. Both cefepime and taniborbactam are predominantly renally excreted and are likely to require...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Open Forum Infect Dis
Autores principales: Geibel, Brooke, Dowell, James A, Marbury, Thomas C, Smith, William, McGovern, Paul C, Richards, Cynthia, Henkel, Tim
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7777653/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.1500
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares